Core Insights - The company Shijiazhuang Pharmaceutical Group (石四药集团) has received approval from the National Medical Products Administration of China for three active pharmaceutical ingredients (APIs): Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin [1] - Among these, Sodium Phosphate of Levofloxacin is the third API approved for use in China by domestic companies [1] Group 1: Product Approvals - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as for lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is mainly used for treating severe amoebic infections of the intestine and liver, infections caused by anaerobic bacteria sensitive to Metronidazole post-surgery, and for preventing infections from anaerobic bacteria during surgical procedures [1]

Core Viewpoint - The announcement from the company indicates that three active pharmaceutical ingredients (APIs) have been approved by the National Medical Products Administration of China for use in marketed formulations, highlighting the company's growth in the pharmaceutical sector [1] Group 1: Product Approvals - The three APIs approved are Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin, with the latter being the third domestic company to receive approval [1] - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is used for treating severe amoebic infections of the intestine and liver, as well as for preventing infections caused by anaerobic bacteria during surgical procedures [1]

Core Viewpoint - The announcement highlights that the company Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for three active pharmaceutical ingredients, indicating a significant milestone in expanding its product offerings in the market [1] Group 1: Product Approvals - The three approved active pharmaceutical ingredients are Fenofibrate, Fenofibric Acid, and Sodium Phosphate of Levofloxacin, with the latter being the third domestic company to receive such approval [1] - Fenofibrate and Fenofibric Acid are primarily used for treating hyperlipidemia and hypercholesterolemia, as well as lowering triglyceride levels in patients with severe hypertriglyceridemia [1] - Sodium Phosphate of Levofloxacin is mainly used for treating severe amoebic infections of the intestines and liver, as well as for preventing infections caused by anaerobic bacteria during surgical procedures [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 石四藥集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 第 2 頁 共 10 頁 v 1.1.1 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02005 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 HKD | | 200,000,000 | 本月 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 非諾貝特及非諾貝特酸膽鹼主要用於治療高血脂症和高膽固醇、降低重度高甘油三酯血症患者 的甘油三酯水平、及用於原發性高膽固醇血症或混合型血脂異常患者的治療。磷酸左奧硝唑酯 二鈉主要用於治療腸道和肝臟嚴重的阿米巴病、治療奧硝唑敏感厭氧菌引起的手術後感染、及 預防外科手術導致的敏感厭氧菌感染。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的非諾貝特、非諾貝特酸膽鹼、及磷酸左奧硝唑酯二鈉共3個原料藥已獲中國國家藥品 監督管理局批准登記成為在 ...

Core Viewpoint - The company Shijiazhuang Four Medicines Group has received approval from the National Medical Products Administration of China for its Vitamin B6 injection (1ml:0.1g) to pass the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency [1] - It can also be utilized in cases of pregnancy, radiation sickness, and vomiting caused by anticancer drugs, as well as seborrheic dermatitis and hereditary Vitamin B6 dependency syndrome in newborns [1]

Core Viewpoint - The company Shih Sih Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Vitamin B6 injection (1ml:0.1g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency [1] - It can also be utilized in cases of pregnancy, radiation sickness, and vomiting caused by anticancer drugs, seborrheic dermatitis, and hereditary Vitamin B6 dependency syndrome in newborns [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has received approval from the National Medical Products Administration of China for its Vitamin B6 injection (1ml:0.1g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Vitamin B6 injection is primarily used for the prevention and treatment of Vitamin B6 deficiency [1] - It can also be utilized in cases of pregnancy, radiation sickness, and vomiting caused by anticancer drugs, as well as seborrheic dermatitis and hereditary Vitamin B6 dependency syndrome in newborns [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年十一月三日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的維生素 B6 注射液（1ml:0.1g）已取得中國國家藥品監督管理局批准通過仿製藥質量 和療效一致性評價。 維生素 B6 注射液（1ml:0.1g）主要用於維生素 B6 缺乏的預防和治療，也可用於妊娠、放射病 及抗癌藥所致的嘔吐、脂溢性皮炎、新生兒遺傳性維生素 B6 依賴綜合症等。 ...

Summary of Key Points Core Viewpoint - On October 30, 32 Hong Kong-listed companies conducted share buybacks, totaling 34.66 million shares and an aggregate amount of HKD 155 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 12 million shares for HKD 50.23 million, with a highest price of HKD 4.200 and a lowest price of HKD 4.170, bringing its total buyback amount for the year to HKD 129 million [1][2]. - China Petroleum & Chemical Corporation repurchased 4.78 million shares for HKD 19.72 million, with a highest price of HKD 4.220 and a lowest price of HKD 4.100, accumulating a total buyback amount of HKD 794 million for the year [1][2]. - Stone Four Pharmaceutical Group repurchased 5 million shares for HKD 15.41 million, with a highest price of HKD 3.130 and a lowest price of HKD 3.030, totaling HKD 14.81 million in buybacks for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on October 30 was from China Feihe at HKD 50.23 million, followed by China Petroleum & Chemical Corporation at HKD 19.72 million [1][2]. - In terms of share quantity, China Feihe led with 12 million shares repurchased, followed by Stone Four Pharmaceutical Group with 5 million shares and China Petroleum & Chemical Corporation with 4.78 million shares [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Lianlian Digital and Guosheng Tang, with varying amounts and share quantities [1][2]. - The data also includes a detailed table of buybacks from various companies, highlighting their respective share counts, amounts, and price ranges [2][3].